AFFiRiS AG

Parkinson's disease

Atherosclerosis

Welcome

AFFiRiS is an innovative, Vienna-based biotechnology company. Using its proprietary AFFITOME® - technology, it is able to develop customised peptide-based vaccines targeting Alzheimer’s disease, Parkinson's disease, atherosclerosis and other diseases with unmet medical needs.

AFFiRiS was founded by Dr. Walter Schmidt (CEO) and Dr. Frank Mattner (CSO) in late 2003. Based on its business model and its globally unique expertise, AFFiRiS aims to initiate the clinical testing of a new vaccine against thus-far incurable diseases every 2 to 3 years.